转自：前瞻产业研究院 以下数据及分析来自于前瞻产业研究院毛发医疗行业研究小组发布的《中国美容美发行业市场前瞻与投 资规划分析报告》。 毛发医疗行业主要上市公司：雍禾医疗(02279.HK)、仙琚制药(002332)、*ST 美谷(000615)、益盛药业 (002566)、振东制药(300158)、国际医学(000516)、康惠制药(603139)、康缘药业(600557)、康恩贝 (600572)、福瑞达(600223)等 本文核心数据：中国毛发医疗企业竞争梯队;中国毛发医疗行业市场份额;毛发医疗行业集中度 毛发医疗行业代表性企业主要分布在陕西、浙江、吉林、辽宁、山东、江苏等省份，其中陕西、浙江的 企业数量较多，浙江拥有仙琚制药、康恩贝等生发药品生产企业，陕西拥有康惠制药等生发药品生产企 业、国际医学等拥有植发服务的医疗集团。 1、中国毛发医疗行业竞争梯队 从毛发医疗行业竞争梯队看，注册资本超过15亿元的企业主要有康恩贝、华邦健康、国际医学，处于行 业头部地位;5-15亿注册资本的毛发医疗企业主要有福瑞达、振东制药、三生制药、仙琚制药等，处于 一梯队;其余注册资本小于5亿元的毛发医疗企业处于第二梯队。 2、 ...

（编辑 任世碧） 证券日报网讯 1月29日，仙琚制药发布公告称，公司的全资子公司台州仙琚药业有限公司（简称"台州 仙琚药业"）于近日收到由浙江省经济和信息化厅、浙江省财政厅、国家税务总局浙江省税务局联合颁 发的《高新技术企业证书》。本次系台州仙琚药业原高新技术企业证书有效期满后的重新认定。 ...

证券代码：002332 证券简称：仙琚制药 公告编号：2026-004 浙江仙琚制药股份有限公司 关于全资子公司通过高新技术企业重新认定的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 浙江仙琚制药股份有限公司的全资子公司台州仙琚药业有限公司（以下简称"台 州仙琚药业"）于近日收到由浙江省经济和信息化厅、浙江省财政厅、国家税务总局 浙江省税务局联合颁发的《高新技术企业证书》，具体情况如下： 企业名称：台州仙琚药业有限公司 发证日期：2025年12月19日 有效期：三年 本次系台州仙琚药业原高新技术企业证书有效期满后的重新认定，根据《中华人 民共和国企业所得税法》的规定，台州仙琚药业通过高新技术企业重新认定后将连续 三年（即2025年、2026年、2027年）按15%的税率缴纳企业所得税。 台州仙琚药业2025年度已根据相关规定按照15%的企业所得税税率进行财务核算， 上述税收优惠政策不会影响公司2025年度的经营业绩。 特此公告。 浙江仙琚制药股份有限公司 董事会 2026年1月30日 证书编号：GR202533003759 ...

Group 1 - The core viewpoint of the article is that Xianju Pharmaceutical (002332) has engaged in preliminary commercialization preparations for the drug Ageng Glucosamine Sodium Injection, but the financial impact on current operations is expected to be minor due to uncertainties in approval and market access [1][1][1] Group 2 - The company has signed various agreements related to the product, but the specific financial amounts have not been disclosed, citing potential commercial confidentiality [1][1] - The product is currently under review, and there are uncertainties regarding its approval and the timeline for market entry, as well as negotiations with health insurance [1][1][1]

Core Viewpoint - Zhejiang Xianju Pharmaceutical Co., Ltd. has signed a tripartite agreement with Hangzhou Aomei Pharmaceutical Co., Ltd. and Aspen (Guang Dong) Pharmaceutical Co., Ltd. for the exclusive marketing of the drug Agerglucoside Sodium Injection in mainland China, indicating a strategic move towards commercialization of the product [1][2][12]. Group 1: Agreement Details - The tripartite agreement allows Aspen to act as the exclusive marketing service provider for Agerglucoside Sodium Injection in mainland China, excluding Hong Kong, Macau, and Taiwan [2][8]. - The commercialization milestone sharing agreement stipulates a 50% split of milestone payments and net sales revenue between Xianju Pharmaceutical and Aomei Pharmaceutical after deducting relevant costs [2][10]. - Additional agreements include a raw material supply agreement and a contract for commissioned production of Agerglucoside Sodium Injection, ensuring a stable supply and quality assurance for the product [3][10]. Group 2: Company Background - Hangzhou Aomei Pharmaceutical Co., Ltd. was established on October 25, 2000, with a registered capital of 69.825291 million RMB, focusing on medical research, chemical product sales, and drug production [4][5]. - Aspen (Guang Dong) Pharmaceutical Co., Ltd. was founded on January 31, 1997, with a registered capital of 57.6 million USD, specializing in the wholesale and production of various pharmaceutical products [5][6]. Group 3: Impact on Company - The signing of these agreements is a preparatory step for the future commercialization of Agerglucoside Sodium Injection, leveraging Aspen's extensive market experience in the anesthesia field to enhance product promotion and sales [12]. - The agreements clarify the revenue distribution and supply assurance mechanisms for the product post-approval, which is beneficial for the product's market entry and aligns with the interests of the company and its shareholders [12][13].

Core Viewpoint - Xianju Pharmaceutical has established strategic partnerships for the development and commercialization of the drug Aomikson Sodium (also known as Ageng Glucose Sodium Injection) with Hangzhou Aomei Pharmaceutical and Aishijian (Guangdong) Pharmaceutical [1][2] Group 1: Agreements and Collaborations - On December 17, 2015, Xianju Pharmaceutical signed a development cooperation agreement for Aomikson Sodium with Hangzhou Aomei [1] - A supplementary agreement was signed on April 16, 2021, to further the development of Aomikson Sodium [1] - A strategic cooperation framework agreement was signed on January 12, 2023, to outline the collaboration on Aomikson Sodium [1] Group 2: Recent Developments - On January 16, 2026, Xianju Pharmaceutical, Hangzhou Aomei, and Aishijian signed a tripartite agreement to authorize Aishijian as the exclusive marketing service provider for Aomikson Sodium in mainland China [2] - The commercialization milestone sharing ratio for Aomikson Sodium is set at 50% for both Xianju Pharmaceutical and Hangzhou Aomei [2] - A procurement supply agreement and a supplementary agreement for contract manufacturing of Aomikson Sodium were also signed on January 16, 2026 [2]

Core Viewpoint - Xianju Pharmaceutical has entered into a tripartite agreement with Hangzhou Aomei and Aishijian for the exclusive marketing of Ageng Glucosamine Sodium Injection in mainland China, excluding Hong Kong, Macau, and Taiwan [1] Group 1 - The agreement designates Aishijian as the exclusive marketing service provider for Ageng Glucosamine Sodium Injection in mainland China [1] - Xianju Pharmaceutical and Hangzhou Aomei have established a milestone revenue-sharing agreement, with both parties sharing 50% of the commercialization milestone revenue [1] - The net revenue from commercialization sales in mainland China will also be shared equally, with both companies receiving 50% after deducting relevant expenses [1] Group 2 - Xianju Pharmaceutical and Hangzhou Aomei have signed a procurement supply agreement for the raw materials of Ageng Glucosamine Sodium and a supplementary agreement for the commissioned production of the injection [1] - Ageng Glucosamine Sodium Injection is classified as a Class 1 new drug and is a targeted muscle relaxant [1]

Core Viewpoint - The collaboration between Xianju Pharmaceutical and Hangzhou Aomei Pharmaceutical focuses on the development, production, and commercialization of the drug Aomeikongsu Sodium (also known as Ageng Glucose Sodium Injection) [1][2] Group 1: Agreements and Collaborations - Xianju Pharmaceutical signed multiple agreements with Hangzhou Aomei, including the initial development cooperation agreement in December 2015, a supplementary agreement in April 2021, and a strategic cooperation framework agreement in January 2023 [1] - On January 16, 2026, Xianju Pharmaceutical, Hangzhou Aomei, and Aishijian (Guangdong) Pharmaceutical Co., Ltd. entered into a tripartite agreement to authorize Aishijian as the exclusive marketing service provider for Ageng Glucose Sodium Injection in mainland China [2] - The commercialization milestone sharing agreement and sales revenue sharing agreement stipulate that both Xianju Pharmaceutical and Hangzhou Aomei will share 50% of the commercialization milestones and net sales revenue after deducting relevant expenses [2] Group 2: Product Naming and Regulatory Aspects - The Chinese common name for Aomeikongsu Sodium and its injection form is officially recognized as Ageng Glucose Sodium and Ageng Glucose Sodium Injection, respectively [1] - The agreements outline specific terms regarding the procurement of raw materials and contract manufacturing for Ageng Glucose Sodium Injection [2]

证券代码：002332 证券简称：仙琚制药 公告编号：2026-003 浙江仙琚制药股份有限公司 关于签订共同授权合作产品中国境内推广服务之三方协议 及相关协议的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 浙江仙琚制药股份有限公司（以下简称"公司"、"仙琚制药"）与杭州奥默医 药股份有限公司（以下简称"杭州奥默"）于2015年12月17日签署了《1.1类新药奥 美克松钠产品开发合作协议》（公告编号：2015-058）、2021年4月16日签署了《1.1 类新药奥美克松钠产品开发合作协议》之补充协议（公告编号：2021-014）、2023年 1月12日签署了《1.1类新药靶向性肌松拮抗剂奥美克松钠产品战略合作框架协议》等 相关协议（"原协议"），就奥美克松钠（阿更葡糖钠注射液）（以下简称"合作产 品"）的研发、生产及商业化合作达成各项约定。 根据国家药典委员会2025年10月《关于申报奥美克松钠产品通用名称的函》："奥 美克松钠"、"奥美克松钠注射液"，中文通用名称为"阿更葡糖钠"、"阿更葡糖 钠注射液"。以下各协议中的"奥美克松钠注射液"均指"阿更葡 ...

Group 1 - The company has announced a partnership with Hangzhou Aomei Pharmaceutical Co., Ltd. to jointly authorize Aishijian (Guangdong) Pharmaceutical Co., Ltd. as the exclusive marketing service provider for Agomelatine injection in mainland China (excluding Hong Kong, Macau, and Taiwan) [1] - A milestone revenue-sharing agreement and sales revenue-sharing agreement have been signed, with both parties agreeing to share commercial revenue equally at 50% [1] - Additionally, a raw material procurement supply agreement and a supplementary contract for commissioned processing production have been established [1]